Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
|出版日期||內容資訊||英文 136 Pages
|腸泌素（Incretin）藥物：糖尿病療法市場與治療法開發 Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments|
|出版日期: 2015年02月25日||內容資訊: 英文 136 Pages||
The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.
The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and a M.A in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm in the Research Triangle Park area of North Carolina and which focused on pharmaceuticals and biotechnology. Before joining that firm, Lawson published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.